SRTA Strata Critical Medical, Inc.
Transportation Services · Nasdaq · SEC CIK 1779128 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY68.4%
TTM net income YoY-161.4%
TTM EPS YoY-160.0%
Revenue 3-yr CAGR9.2%
Net income 3-yr CAGR—
Margins
Gross margin21.6%
Operating margin-6.6%
Net margin-8.8%
FCF margin0.3%
EBITDA margin-3.2%
Returns
ROE-8.9%
ROA-7.5%
ROIC (approx.)-5.9%
Asset turnover0.85x
Leverage & solvency
Liabilities / assets16.0%
Debt / equity0.00x
Current ratio2.77x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.43x
Accruals ratio-10.7%
Payout ratio—
Capex / revenue3.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $197.14M | $146.82M |
| Cost of revenue | $156.01M | $117.23M |
| Gross profit | $41.13M | $29.59M |
| SG&A expense | $60.88M | $50.86M |
| Operating income | -$22.35M | -$22.52M |
| Pretax income | -$20.07M | -$16.16M |
| Income tax | $0 | $0 |
| Net income | $41.35M | -$27.31M |
| EBITDA | -$14.17M | -$16.56M |
| EPS (basic) | 0.50 | -0.35 |
| EPS (diluted) | 0.50 | -0.35 |
| Weighted avg. shares (diluted) | 82.09M | 77.50M |
| Banking | ||
| Net interest income | — | $7.21M |
| Balance sheet | ||
| Cash & equivalents | $31.23M | $19.65M |
| Short-term investments | $30.26M | $108.76M |
| Receivables | $39.96M | $19.82M |
| Current assets | $126.19M | $160.74M |
| PP&E, net | $36.44M | $28.46M |
| Goodwill | $88.21M | $15.54M |
| Intangibles | $47.50M | $7.96M |
| Total assets | $325.47M | $256.68M |
| Current liabilities | $19.79M | $22.73M |
| Total liabilities | $46.40M | $34.74M |
| Shareholders' equity | $279.07M | $221.94M |
| Cash flow statement | ||
| Operating cash flow | -$48.91M | -$2.52M |
| Capital expenditure | $9.60M | $30.86M |
| Free cash flow | -$58.51M | -$33.38M |
| Investing cash flow | $69.75M | -$1.02M |
| Financing cash flow | -$8.91M | -$5.76M |
| Depreciation & amortization | $8.19M | $5.96M |
| Stock-based compensation | $17.83M | $19.89M |
| Share buybacks | $0 | $244,000 |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.